Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Emiltatug Ledadotin (Emi-Le, XMT-1660)

Stage Phase 1/2

Sponsor Servier (registry sponsor Day One Biopharmaceuticals)

Route intravenous

Modality antibody-drug conjugate

Class B7-H4-directed ADC

Mechanism B7-H4 antibody with auristatin-F HPA payload (DAR 6)

Target B7-H4 (VTCN1)

Sources

company_release, as of 2026-11-07

https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026

Servier release, 06.01.2026 (company release; opened 2026-10-27), ASCO 2026 oral abstract 6010 (doi 10.1200/JCO.2026.44.16_suppl.6010; abstract not opened): Emi-Le (B7-H4 ADC) Phase 1; 45 evaluable ACC patients ORR 35.6% (one CR), DCR 82.2%; post hoc aggressive subtype n 32 ORR 46.9%, DCR 81.3%, median PFS 7.8 months; TRAEs leading to discontinuation 3.9% (all patients); grade 3 AST increase 20% and proteinuria 23%; no grade 4 or 5 TRAEs. FDA Breakthrough Therapy designation (ACC with solid histology or high-grade transformation). Preliminary.

Brief source A15

company_release, as of 2026-11-07

https://servier.mediaroom.com/2026-10-19-Servier-Announces-First-Patients-Dosed-in-Pivotal-Phase-2-EMBLEM-1-Cohort-Evaluating-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma

Servier release, 10.19.2026 (company release; opened 2026-10-27): first patients dosed in the pivotal Phase 2 EMBLEM-1 cohort (NCT05377996); primary endpoint ORR per RECIST 1.1 (confirmed CR or PR); Breakthrough Therapy designation; no FDA-approved systemic option; ACC diagnosed in about four per million people per year (company figure). No filing date disclosed.

Brief source A16

publication, as of 2026-11-07

https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma

OncLive, 06.16.2026 (trade press on the ASCO 2026 oral presentation; opened 2026-10-27): Emi-Le 95% CI for ORR 46.9% is 29.1% to 65.3%; DoR 6.4 months (aggressive subtype) and 7.4 months (n 45); ACC cohort n 48: any grade TRAEs 100%, grade 3 TRAEs 79.2% (51.1% in all 180), TRAE discontinuation 2.1% (1 patient), dose reduction 45.8%, dose delay 56.3%; proteinuria the leading cause of dose changes, proteinuria-related dose reductions fell from 38.9% to 20% after a monitoring amendment; EMBLEM-1 dose 80 mg/m2 every 4 weeks, cap 160 mg; Breakthrough designation May 2026; historical median PFS of 2 to 3 months in aggressive ACC-I (presenter, citing prior trials); about 30% to 40% of patients have the aggressive phenotype.

Brief source A17

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05377996

A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)

Registry NCT05377996

Phase Phase 1/2

Status Recruiting

Enrollment 360

Start 2022-08-15

Primary completion 2027-02

Study completion 2027-12

Catalyst Primary completion. 02.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst EMBLEM-1 first patients dosed. 10.19.2026. Company release; event occurred.

Emi-Le, ACC efficacy cohort

Dose Phase 1 doses (not stated in source)

Regimen every 4 weeks

Population R/M ACC, evaluable (n = 45)

Estimand Single arm

objective response rate: 35.6%, ASCO 2026

disease control rate: 82.2%, ASCO 2026

median duration of response: 7.4 months, ASCO 2026

Emi-Le, post hoc aggressive subtype

Dose Phase 1 doses (not stated in source)

Regimen every 4 weeks

Population ACC with solid histology or high-grade transformation (n = 32, post hoc)

Estimand Single arm

objective response rate: 46.9%, ASCO 2026; post hoc

median progression-free survival: 7.8 months, ASCO 2026; post hoc

median duration of response: 6.4 months, ASCO 2026; post hoc

Emi-Le, ACC safety cohort

Dose Phase 1 doses (not stated in source)

Regimen every 4 weeks

Population ACC safety population (n = 48)

Estimand Single arm

grade 3 treatment-related adverse events: 79.2%, ASCO 2026

treatment-related discontinuation: 2.1%, ASCO 2026

dose reduction: 45.8%, ASCO 2026

EMBLEM-1 pivotal Phase 2 cohort

Dose 80 mg/m2, cap 160 mg

Regimen every 4 weeks

Population aggressive ACC (solid histology or high-grade transformation); primary endpoint ORR

Estimand Single arm